Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
公司代码MANE
公司名称Veradermics Inc
上市日期Feb 04, 2026
CEOWaldman (Reid Alexander)
员工数量19
证券类型Ordinary Share
年结日Feb 04
公司地址- -
城市- -
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家- -
邮编- -
电话- -
网址- -
公司代码MANE
上市日期Feb 04, 2026
CEOWaldman (Reid Alexander)